Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Long Beach Memorial Medical Center
mi
from
Long Beach, CA
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Long Beach Memorial Medical Center
mi
from
Long Beach, CA
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Children´s Hospital Los Angeles, Hemophilia Comprehensive Care Center, Division of Pediatric Hematology/Oncology
mi
from
Los Angeles, CA
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Children´s Hospital Los Angeles, Hemophilia Comprehensive Care Center, Division of Pediatric Hematology/Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Valley Children's Hospital
mi
from
Madera, CA
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Valley Children's Hospital
mi
from
Madera, CA
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Children'S Hospital of S.W. Florida
mi
from
Fort Myers, FL
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Children'S Hospital of S.W. Florida
mi
from
Fort Myers, FL
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
BIODORON
mi
from
Hollywood, FL
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
BIODORON
mi
from
Hollywood, FL
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Nemours Children's Clinic
mi
from
Jacksonville, FL
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Nemours Children's Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Tampa Children'S Hospital At St. Joes
mi
from
Tampa, FL
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Tampa Children'S Hospital At St. Joes
mi
from
Tampa, FL
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
University of Southern Florida
mi
from
Tampa, FL
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
University of Southern Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Rush-Presbyterian-St. Luke's Medical Center
mi
from
Chicago, IL
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Rush-Presbyterian-St. Luke's Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Children´s Memorial Hospital
mi
from
Chicago, IL
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Children´s Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
University of Iowa Hospitals and Clinics, Iowa Regional Hemophilia Center, Department of Pediatrics
mi
from
Iowa City, IA
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
University of Iowa Hospitals and Clinics, Iowa Regional Hemophilia Center, Department of Pediatrics
mi
from
Iowa City, IA
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Tulane University Hospital & Clinic
mi
from
New Orleans, LA
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Tulane University Hospital & Clinic
mi
from
New Orleans, LA
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
University of Michigan Med. Ctr Htc
mi
from
Ann Arbor, MI
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
University of Michigan Med. Ctr Htc
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Henry Ford Hospital
mi
from
Detroit, MI
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
PHS DEVOS CHILDRENS Hospital
mi
from
Grand Rapids, MI
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
PHS DEVOS CHILDRENS Hospital
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Munson Medical Center
mi
from
Traverse City, MI
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Munson Medical Center
mi
from
Traverse City, MI
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
University of Mississippi Medical Center
mi
from
Jackson, MS
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
St. Louis Children's Hospital
mi
from
Saint Louis, MO
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
St. Louis Children's Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Ted R. Montoya Hemophilia Treatment Center
mi
from
Albuquerque, NM
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Ted R. Montoya Hemophilia Treatment Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
North Carolina Baptist Hospital, Hematology/Oncology Medical Center Boulevard
mi
from
Winston-Salem, NC
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
North Carolina Baptist Hospital, Hematology/Oncology Medical Center Boulevard
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Phs Childrens Hosp Med Ctr Akron
mi
from
Akron, OH
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Phs Childrens Hosp Med Ctr Akron
mi
from
Akron, OH
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Children´s Hospital Medical Center Pharmacy, Hemophilia Treatment Center
mi
from
Cincinnati, OH
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Children´s Hospital Medical Center Pharmacy, Hemophilia Treatment Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Youngstown HTC
mi
from
Youngstown, OH
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Youngstown HTC
mi
from
Youngstown, OH
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Presbyterian Med Ctr
mi
from
Philadelphia, PA
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Presbyterian Med Ctr
mi
from
Philadelphia, PA
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
St. Christopher´s Hospital for Children, Section of Hematology/Oncology
mi
from
Philadelphia, PA
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
St. Christopher´s Hospital for Children, Section of Hematology/Oncology
mi
from
Philadelphia, PA
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
University of Tennessee Medical Center
mi
from
Knoxville, TN
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
University of Tennessee Medical Center
mi
from
Knoxville, TN
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Baylor College of Medicine
mi
from
Houston, TX
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Phs-So Tx Hemo Ctr-San Antonio
mi
from
San Antonio, TX
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Phs-So Tx Hemo Ctr-San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated:  10/19/2017
Children's Hospital of The King's Daughters
mi
from
Norfolk, VA
ADVATE Post Authorization Safety Surveillance
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Status: Enrolling
Updated: 10/19/2017
Children's Hospital of The King's Daughters
mi
from
Norfolk, VA
Click here to add this to my saved trials
Osteoporosis and MRI Study in Hemophilia
Bone and Joint Health in an Adult Hemophilia Population
Status: Enrolling
Updated:  10/19/2017
Los Angeles Orthopedic Hospital
mi
from
Los Angeles, CA
Osteoporosis and MRI Study in Hemophilia
Bone and Joint Health in an Adult Hemophilia Population
Status: Enrolling
Updated: 10/19/2017
Los Angeles Orthopedic Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Little Rock, AR
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
mi
from
Washington, D.C.,
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Atlanta, GA
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Chicago, IL
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Peoria, IL
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Peoria, IL
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Indianapolis, IN
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Iowa City, IA
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
New Orleans, LA
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Detroit, MI
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
Minneapolis, MN
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
New Hyde Park, NY
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated:  10/19/2017
Clinical Research Facility
mi
from
New York, NY
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Status: Enrolling
Updated: 10/19/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials